How Artificial General Intelligence Could Transform Drug Discovery and Disease Treatment
Developers claim that achieving artificial general intelligence may accelerate the search for cures by processing vast biomedical data far beyond human capacity.
AI researchers are optimistic that artificial general intelligence will eventually handle the most complex biomedical problems, turning the exhaustive drug-discovery process into a faster, data-driven exercise. Papers in the Journal of Pharmaceutical Analysis and Drug, Design, Development and Therapy highlight AI's ability to reduce reliance on serendipity, lower costs, and shorten timelines for candidate selection and trial planning.
Despite these gains, critics note that clinical trials still depend on human participants and rigorous safety reviews, which could lengthen timelines under heightened scrutiny. Moreover, AGI's performance is limited by the quality and accessibility of fragmented scientific datasets. The discussion calls for coordinated policy frameworks to ensure responsible deployment of such powerful technologies.
Why it matters
Advances in AGI could reshape how medicines are discovered, potentially lowering costs and speeding access to treatments.
In this story
